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cute HIV-1 infection. Additional data will be presented on
unctional avidity, phenotyping and kinetics across the group
ver the ﬁrst 6 months of infection. Discussion will focus on
ow these results, together with the studies investigating
ew immunogens may direct more effective design of HIV-1
cell vaccines. Supported by the NIAD Center for HIV/AIDS
accine Immunology grant # U19 AI067854.
oi:10.1016/j.ijid.2010.02.1528
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HIV-1 subtype C viruses elicit potent but highly type-
peciﬁc neutralizing antibodies within the ﬁrst year of
nfection. In order to determine the speciﬁcity and evolution
f these autologous neutralizing antibodies, we examined
eutralization escape in four individuals infected with HIV-
subtype C from the CAPRISA 002 cohort in Durban, South
frica. Early neutralizing responses recognized a very lim-
ted number of epitopes, with antibodies that recognize new
pitopes evolving sequentially. In addition, only two regions
f the envelope were targeted by these antibodies, sug-
esting there might be common vulnerabilities in the HIV-1
ubtype C transmitted envelope. We have shown that type-
peciﬁc responses have a short term affect on viral load
hich is lost with the emergence of viral escape mutants.
actors that contribute to the development of broadly cross-
eactive neutralizing antibodies, those which would ideally
e elicited by an HIV vaccine, are largely unknown. We
ave examined the evolution of neutralization breadth in
he CAPRISA 002 cohort, and shown that cross-neutralizing
ntibodies develop in about a quarter of infected individuals
y 3 years post-infection. Generally breadth develops incre-
entally suggesting the possibility that multiple antibodies
ediate breadth, and/or that breadth is conferred by the
aturation of a single speciﬁcity. In one case, the develop-
ent of breadth could be attributed to a single neutralizing
ntibody speciﬁcity. In the CAPRISA 002 cohort, as well as in
cross-sectional cohort of chronically infected individuals,
e have explored the targets of cross-reactive antibodies
hich mediate breadth using an array of methodologies
ncluding peptide and protein adsorptions and the use of
himeric viruses. We have shown that multiple epitopes on
he envelope glycoprotein are involved in the cross-reactive
eutralization elicited during natural HIV-1 infection, many
f which are yet to be determined.
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Even with a growing recognition that HIV doesn’t dis-
riminate by race, gender, socioeconomic status or sex
rientation, the developing world accounts for 90% of the
lobal HIV burden. Sub-Saharan Africa, which accounts for
wo-thirds of the global HIV infections, Injecting Drug Users,
en who have Sex with Men, and Commercial Sex Workers
are a disproportionate burden of the HIV epidemic. Recent
IV surveillance studies in African countries at best show
tabilization of the epidemic or at worst, slight increases in
ountries like Uganda.
Clearly, the HIV research community recognizes that
dditional new biomedical prevention modalities are
equired to augment existing HIV prevention strategies.
Incidence modeling based on as relatively low efﬁcacy
s 30% for a Pre-Exposure Prophylaxis (PrEP) regimen or a
opical Microbicide has provides a glimmer of hope based on
umber of new HIV infections prevented through such new
odalities. However, scientists need to prove efﬁcacy for
hese new regimens ﬁrst.
Several international collaborations with the develop-
ng world have been formed to enable us conduct clinical
esearch that meets international standards. Phase IIB and
hase III HIV PrEP and Microbicide trials are being conducted
n nine countries globally, involving over 20,000 participants
n the various high risk groups and across different HIV
ransmission routes. Each study is being overseen by regula-
ory agencies both within the developing and the developed
orld.
The major lessons learned to date are that; North-South
ollaborative partnerships are critical to realizing the hope
f ﬁnding new prevention modalities to be added to the HIV
revention tool kit for the most-at-risk groups. Secondly,
ith these collaborations, the developing world has devel-
ped capacity to conduct of clinical research that conforms
o international standards for licensure of new products or
hange of indication of existing drugs/products in the devel-
ping world.
oi:10.1016/j.ijid.2010.02.1530
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It has been exactly 500 years since the ﬁrst recognized
nﬂuenza pandemic appeared and spread around the world
n 1510. Since that time, at least 13 additional inﬂuenza
